21 November 2025 | 5:56PM HKT Equity Research Tigermed (3347.HK) Investor feedback post recent upgrade: New orders outweigh impairment risks in driving recovery; Reiterate Buy | 3347.HK | 12m Price Target: HK$63.40 | Price: HK$38.32 | Upside: 65.4% | | --- | --- | --- | --- | | 300347.SZ | 12m Price Target: Rmb78.70 | Price: Rmb50.69 | Upside: 55.3% | Following our upgrade of Tigermed's rating (see link), the stock rallied after the 3Q results but later retraced to previous levels. Investor feedback reflect ...